Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Complement C1s subcomponent (activated) is a serine protease that forms part of the C1 complex, the first component initiating the classical pathway of the complement system[1][3][6]. In its active form, C1s cleaves complement proteins C4 and C2, leading to the assembly of C3 convertase and propagation of the complement cascade. The classical complement pathway facilitates pathogen clearance, opsonization, and regulation of immune complexes. Dysregulation or aberrant activation of C1s is implicated in various autoimmune diseases, infections, and some cancers. C1s, together with C1r and C1q, comprises the C1 complex; its activation is a therapeutic target, and inhibitors such as monoclonal antibodies (e.g., sutimlimab) are being developed and used clinically[6]. Safety challenges include potential immunosuppression and increased infection risk when C1s function is blocked[6].
Inhibition of serine protease activity Blockade of C4 and C2 cleavage to prevent downstream complement activation
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Complement C1s subcomponent (activated) (C1s).